Equities Analysts Offer Predictions for TYRA FY2024 Earnings

Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) - HC Wainwright decreased their FY2024 EPS estimates for shares of Tyra Biosciences in a report issued on Monday, November 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($1.59) per share for the year, down from their previous forecast of ($1.53). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Tyra Biosciences' current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Tyra Biosciences' Q4 2024 earnings at ($0.52) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at ($2.17) EPS.

Several other equities analysts have also weighed in on TYRA. Bank of America raised shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and lifted their target price for the company from $22.00 to $31.00 in a report on Friday, October 18th. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price objective for the company. Wedbush reiterated an "outperform" rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. Finally, Oppenheimer raised their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research report on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $31.00.

Tyra Biosciences Stock Down 1.3 %

TYRA stock traded down $0.20 during trading on Wednesday, hitting $15.74. 271,852 shares of the company traded hands, compared to its average volume of 191,146. Tyra Biosciences has a 1 year low of $10.60 and a 1 year high of $29.60. The stock's 50-day simple moving average is $21.62 and its 200 day simple moving average is $20.01.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01).

Insider Buying and Selling

In related news, CFO Alan Fuhrman purchased 9,500 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the transaction, the chief financial officer now directly owns 12,849 shares in the company, valued at approximately $205,584. This trade represents a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO Alan Fuhrman purchased 9,500 shares of the company's stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the transaction, the chief financial officer now owns 12,849 shares of the company's stock, valued at $205,584. This trade represents a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nina S. Kjellson sold 11,078 shares of the stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total value of $179,131.26. Following the completion of the transaction, the director now directly owns 472,207 shares of the company's stock, valued at approximately $7,635,587.19. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 101,050 shares of company stock valued at $2,235,492. 15.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently added to or reduced their stakes in TYRA. Oppenheimer & Co. Inc. purchased a new position in Tyra Biosciences in the first quarter valued at $977,000. Vanguard Group Inc. boosted its stake in shares of Tyra Biosciences by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company's stock valued at $14,757,000 after buying an additional 140,833 shares during the period. American Century Companies Inc. increased its stake in shares of Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock worth $2,723,000 after buying an additional 145,346 shares during the period. Perceptive Advisors LLC raised its holdings in Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock valued at $16,108,000 after acquiring an additional 338,208 shares in the last quarter. Finally, Ensign Peak Advisors Inc purchased a new position in Tyra Biosciences in the second quarter worth approximately $3,047,000. Hedge funds and other institutional investors own 84.14% of the company's stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.